Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments (2018 - 2026)

Arcturus Therapeutics Holdings' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $211.4 million for Q1 2026.

• Quarterly Cash & Current Investments fell 17.25% year-over-year to $211.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.4 million (down 17.25% YoY) and the FY2025 annual result came in at $230.9 million, down 33.82% from the prior year.
• Cash & Current Investments was $211.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $230.9 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $391.9 million in Q4 2022 and bottomed at $211.4 million in Q1 2026.
• A 5-year average of $295.7 million and a median of $311.9 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 42.57% — and 2023, when it surged 31.24%.
• Arcturus Therapeutics Holdings' Cash & Current Investments stood at $391.9 million in 2022, then decreased by 11.45% to $347.0 million in 2023, then advanced by 0.55% to $348.9 million in 2024, then plunged by 33.82% to $230.9 million in 2025, then retreated by 8.46% to $211.4 million in 2026.
• Business Quant data shows ARCT's Cash & Current Investments at $211.4 million in Q1 2026, $230.9 million in Q4 2025, and $235.4 million in Q3 2025.